Resultados de Búsqueda por Autor

artículo

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00

Publicado por
Colleoni, M, Gray, KP, Gelber,S, Láng, I, Thürlimann, B, Gianni, L, Abdi, EA, Gomez, HL, inderholm, BK, Puglis,i F, Tondini, C, Kralidis, E, Eniu, A, Cagossi, K, Rauch, D, Chirgwin, J, Gelber, RD, Regan, MM, Coates, AS, Price, KN, Viale, G, Goldhirsch, A

Publicado 2017

Enlace

Purpose: To evaluate the benefit of low-dose cyclophosphamide and methotrexate (CM) maintenance, which previously demonstrated antitumor activity and few adverse effects in advanced breast cancer, in early breast cancer. Patients and methods: International Breast Cancer Study Group (IBCSG) Trial 22-00, a randomized phase III clinical trial, enrolled 1,086 women (1,081 intent-to-treat) from November 2000 to December 2012. Women with estrogen receptor- and progesterone receptor-negative (< 10% positive cells by immunohistochemistry) early breast cancer any nodal and human epidermal growth factor receptor 2 status, were randomly assigned anytime between primary surgery and 56 days after the first day of last course of adjuvant chemotherapy to CM maintenance (cyclophosphamide 50 mg/day orally continuously and methotrexate 2.5 mg twice/day orally on days 1 and 2 of every week for 1 year) or t...

artículo

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Publicado por
Saha, P, Regan, MM, Pagani, O, Francis, PA, Walley, BA, Ribi, K, Bernhard, J, Luo, W, Gómez, HL, Burstein, HJ, Parmar, V, Torres, R, Stewart, J, Bellet, M, Perelló, A, Dane, F, Moreira, A, Vorobiof, D, Nottage, M, Price, KN, Coates, AS, Goldhirsch, A, Gelber, RD, Colleoni, M, Fleming, GF, SOFT TEXT Investigators, International Breast Cancer Study Group

Publicado 2017

Enlace

Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled in the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). Methods In SOFT, women still premenopausal after surgery with or without chemotherapy were randomly assigned to tamoxifen alone, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. In TEXT, all received OFS with or without concomitant chemotherapy and were randomly assigned to exemestane plus OFS or tamoxifen plus OFS. We summarize treatment efficacy, quality of life, and adherence of the cohort of women younger than 35 years in SOFT and TEXT, alongside data from the cohort of older premenopausal women. Results For 240 human epidermal growth factor receptor 2-negative patients younger than 35 years enrolled in SOFT after receivin...